NCT04159727|Completed
Gut Microbiota Dysbiosis and Translocation During IBD and Parkinson
Medibiote1
Loading search results
Medibiote1
Sponsor study identifier
interventional
15
1 country
1
Study Start
March 28, 2019
Actual (reported)Primary Completion
February 13, 2020
Actual (reported)Study Completion
February 13, 2020
Actual (reported)Inflammatory bowel diseases (IBD) and Parkinson disease (PD) are complex and multifactorial pathologies. Gut microbiota seems to play an active role. Indeed the digestive microbiota of patients with IBD or PD exhibits different compositions compared with asymptomatic subjects. Bacterial translocation from gut to blood has been reported.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 13, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 28, 2019
Actual (reported)October 16, 2019
Actual (reported)November 12, 2019
Actual (reported)February 13, 2020
Actual (reported)February 13, 2020
Actual (reported)16S RNA sequencing in stool sample
16S RNA sequencing to identify species constituting the microbiota in the stool
2 years
16S RNA sequencing in blood sample
16S RNA sequencing to identify species constituting the microbiota in the blood
2 years
Stool quantification of key bacteria associated with intestinal barrier permeability.
To determine stool rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR
2 years
Blood quantification of key bacteria associated with intestinal barrier permeability.
To determine blood rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR
2 years
20 patients suffering from IBD 10 patients suffering from PD
30 asymptomatic subjects matched to patients on age, sexe and BMI
High throughput sequencing and quantitative PCR
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
European Hospital
Marseille, Bouches-du Rhone, 13003, France
Philippe HALFON, MD, PhD
Hôpital Européen Marseille
15 participants (actual enrollment reported by the registry).
First Submitted
October 16, 2019
First Posted
November 12, 2019
Study Start
March 28, 2019
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
February 13, 2020
Actual (reported)Study Completion
February 13, 2020
Actual (reported)Last Updated
September 16, 2025
Record last verified: 2019-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: